Sonrotoclax is a medicine used to treat mantle cell lymphoma, a blood cancer, when it has come back after other treatments. It is taken as a pill by mouth. It works by blocking a protein called BCL-2 that helps cancer cells stay alive, so the cancer cells die.
Every report comes from a Lived member, sent anonymously.
Have you tried Beqalzi (Sonrotoclax) for Mantle-Cell Lymphoma?
Sonrotoclax, sold as Beqalzi, is a targeted cancer pill for adults with mantle cell lymphoma, a rare and often aggressive type of non-Hodgkin lymphoma that starts in B cells, a kind of white blood cell. It is used when the lymphoma has come back or stopped responding after at least two earlier treatments, one of which was a BTK (Bruton's tyrosine kinase) inhibitor, a type of targeted lymphoma pill such as ibrutinib (Imbruvica), zanubrutinib (Brukinsa) or pirtobrutinib (Jaypirca). The FDA approved Beqalzi in 2026 under accelerated approval. That means the decision rested on how often and how long the lymphoma shrank in a clinical trial, not yet on proof that people live longer. A confirmatory study is still required. It is not approved for children.
Cells have a built-in self-destruct process that removes damaged or unneeded cells. A protein called BCL-2 (B-cell lymphoma 2) acts as a brake on that process. Many lymphoma cells make too much BCL-2, which helps them survive when they should die and can make them harder to kill with other treatments. Sonrotoclax attaches to BCL-2 and frees the signals it was holding back, so the lymphoma cells switch their self-destruct process back on. It belongs to the same family of medicines as venetoclax, an older BCL-2 inhibitor. Because it can kill many cancer cells quickly, the start of treatment needs careful management.
Beqalzi is a tablet taken once a day with a meal, at about the same time each day. Swallow the tablets whole with a glass of water; do not break, chew or crush them. Treatment begins with a 4-week ramp-up using a starter pack. The dose starts at 1 mg and roughly doubles about twice a week until it reaches 160 mg. From week 5 the usual dose is 320 mg (four 80 mg tablets) daily, continued as long as it keeps the lymphoma under control and side effects are manageable. The slow start lets the lymphoma shrink gradually and lowers the risk of tumor lysis syndrome, explained under Side Effects. Before the first dose, the care team checks blood tests, corrects any imbalances and starts a medicine that lowers uric acid. You are asked to drink 6 to 8 glasses of water (about 1.5 to 2 liters) a day starting 1 to 2 days before the first dose, on the first day, on each day the dose goes up, and when restarting after a break. Some people, especially those with a large amount of lymphoma or reduced kidney function, take early doses in the hospital or clinic with IV fluids and closer monitoring. If a dose is missed by less than 8 hours, take it with a meal as soon as possible; if more than 8 hours have passed, skip it and take the next dose as usual. If you vomit after a dose, do not take another that day. If treatment is paused, do not restart on your own: after a break of more than a week the care team usually restarts at a lower dose and steps it up again, and old blister packs should not be reused without their advice.
The most common side effects in the main trial were fatigue, swelling in the legs or elsewhere, diarrhea, constipation, rash, fever and muscle or bone pain. Blood tests often show low white blood cells, red blood cells and platelets. Tumor lysis syndrome is the main early danger. When many cancer cells break down at once they release potassium, phosphate and uric acid into the blood, which can disturb the heart rhythm and damage the kidneys. It can start within hours of the first dose, after any dose increase, or on restarting. It happened in 7% of people in the trial who followed the ramp-up. Contact the care team right away for nausea or vomiting, muscle cramps or twitching, passing much less urine, confusion, a fast or irregular heartbeat, shortness of breath, fever or chills, or unusual tiredness. A seizure or fainting needs emergency care (call 911) rather than a call to the care team. Infections are the other major risk, because the medicine lowers the white blood cells that fight infection. Serious infections, most often pneumonia, affected about 1 in 7 people in the trial, and some were fatal. Call the care team right away for a fever or any sign of infection, such as a new cough, shortness of breath or chills.
Sonrotoclax is broken down in the liver by an enzyme called CYP3A, so medicines that block or speed up this enzyme can make its level dangerously high or too low to work. Strong CYP3A blockers must not be taken when starting sonrotoclax or during the ramp-up because they raise the risk of tumor lysis syndrome; later they require a much lower dose. They include some antifungal medicines often given to prevent infection during cancer treatment (such as posaconazole or voriconazole), some antibiotics (such as clarithromycin) and some HIV medicines (such as ritonavir). Moderate blockers should be avoided at the very start and otherwise need a lower sonrotoclax dose. Medicines that speed up the enzyme, such as the antibiotic rifampin, some seizure medicines (such as carbamazepine or phenytoin) and the herbal supplement St. John's wort, can stop sonrotoclax from working and should be avoided. Grapefruit and grapefruit juice, Seville oranges (often used in marmalade) and star fruit act the same way and should be avoided. Check with the prescriber or pharmacist before starting any prescription, over-the-counter medicine, vitamin or herbal product. Sonrotoclax can harm a developing baby. Women who could become pregnant need a pregnancy test before starting and effective contraception during treatment and for 1 week after the last dose, and men with a partner who could become pregnant also need contraception for the same period. Tell the care team right away about a possible pregnancy. Do not breastfeed during treatment or for 1 week afterward. The medicine may also reduce fertility in men and women. Let the care team know beforehand about kidney problems, gout or high uric acid, or past problems with potassium, phosphorus or calcium levels, since these raise the risk of tumor lysis syndrome.
The first month is the most closely managed part of treatment, with frequent blood tests, extra fluids and sometimes clinic or hospital stays around dose increases. Once the full dose is reached, visits and blood counts continue regularly to watch for infection, low blood counts and changes in kidney function. In the trial that led to approval, about half of people (52%) saw their lymphoma shrink, and about 1 in 6 had no detectable lymphoma on scans. Responses usually appeared within about 2 months and about half of those responses lasted longer than 16 months and half lasted less. These results come from a single trial without a comparison group, in people who had already been through several treatments, so how much sonrotoclax extends life is not yet known. Treatment continues for as long as it controls the lymphoma and side effects stay manageable. Breaks for side effects are common, and the dose can be lowered. If the lymphoma grows, the team will discuss other options, which may include CAR-T cell therapy (a treatment that reprograms a person's own immune cells to attack the lymphoma), other targeted medicines or a clinical trial.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Beqalzi (Sonrotoclax), what you've noticed, or ask the community a question.